- Home
- NXL vs PRPO Comparison
NXL vs PRPO Comparison
Compare NXL & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXL
- PRPO
- Stock Information
- Founded
- NXL 2010
- PRPO N/A
- Country
- NXL United States
- PRPO United States
- Employees
- NXL N/A
- PRPO N/A
- Industry
- NXL Medical Specialities
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- NXL Health Care
- PRPO Industrials
- Exchange
- NXL Nasdaq
- PRPO Nasdaq
- Market Cap
- NXL 10.0M
- PRPO 9.5M
- IPO Year
- NXL 2022
- PRPO N/A
- Fundamental
- Price
- NXL $4.13
- PRPO $6.44
- Analyst Decision
- NXL Strong Buy
- PRPO
- Analyst Count
- NXL 1
- PRPO 0
- Target Price
- NXL $3.00
- PRPO N/A
- AVG Volume (30 Days)
- NXL 4.3M
- PRPO 7.5K
- Earning Date
- NXL 11-08-2024
- PRPO 11-06-2024
- Dividend Yield
- NXL N/A
- PRPO N/A
- EPS Growth
- NXL N/A
- PRPO N/A
- EPS
- NXL N/A
- PRPO N/A
- Revenue
- NXL $162,078.00
- PRPO $17,411,000.00
- Revenue This Year
- NXL $51.39
- PRPO $75.18
- Revenue Next Year
- NXL $177.11
- PRPO N/A
- P/E Ratio
- NXL N/A
- PRPO N/A
- Revenue Growth
- NXL 26.00
- PRPO 31.31
- 52 Week Low
- NXL $0.25
- PRPO $4.31
- 52 Week High
- NXL $4.36
- PRPO $8.49
- Technical
- Relative Strength Index (RSI)
- NXL 68.88
- PRPO 52.41
- Support Level
- NXL $2.40
- PRPO $6.14
- Resistance Level
- NXL $4.36
- PRPO $6.47
- Average True Range (ATR)
- NXL 0.63
- PRPO 0.19
- MACD
- NXL 0.08
- PRPO 0.01
- Stochastic Oscillator
- NXL 79.19
- PRPO 88.00
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.